| A non-interventional, multinational,observational study with isatuximabin patients with relapsed and/orrefractory multiple myeloma (RRMM) |
Ongoing |
SARCLISA® ( isatuximab - irfc ) |
4 |
OBS16577 |
Mouwasat Hospital (Dammam) |
| A Three-Arm, Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Safety and Efficacy of Once-Daily and Twice-Daily Dosing of a Novel Hydrocortisone Acetate 90 mg Suppository Formulation Administered with the Sephure® Suppository Applicator in Subjects with Ulcerative Colitis of the Rectum |
Ongoing |
Hydrocortisone Acetate 90 mg |
3 |
CHS1221 |
King Abdulaziz Medical City NG (Jeddah) |
| International collaborative treatment protocol for infants under one year with KMT2Arearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia (Interfant-21) |
Ongoing |
BLINATUMOMAB |
3 |
SCT22R/016/12 |
King Abdulaziz Medical City NG (Riyadh) |
| A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB WITH LENVATINIB OR SORAFENIB VERSUS LENVATINIB OR SORAFENIB ALONE IN HEPATOCELLULAR CARCINOMA PREVIOUSLY TREATED WITH ATEZOLIZUMAB AND BEVACIZUMAB |
Rejected |
ATEZOLIZUMAB, SORAFENIB |
3 |
MO42541 |
King Abdulaziz Medical City NG (Riyadh) |
| An Open label, Single Center, prospective interventional, phase II clinical trial to evaluate the Efficacy and Safety of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine(BV-AVD) combination escalation in advanced stage classical Hodgkin lymphoma patients who did not achieve interim Positron Emission Tomography (PET2) negativity (defined as Deauville score 3 or less) after 2 cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) |
Rejected |
BRENTUXIMAB VEDOTIN, DACARBAZINE, VINBLASTINE, DOXORUBICIN HYDROCHLORIDE |
2 |
1 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination with Tremelimumab ± Lenvatinib Given Concurrently with Transarterial Chemoembolization (TACE) Compared to TACE Alone in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-3) |
Ongoing |
Lenvatinib (Lenvima) + Durvalumab (Imfinzi) + Tremelimumab (Imjudo) |
3 |
D910VC00001 |
King Faisal Specialist Hospital and Research Center (Riyadh) ,King Abdulaziz Medical City NG (Jeddah), King Fahad Specialist Hospital (Dammam), King Abdulaziz Medical City NG (Riyadh) |
| A Phase III, Multicentre, Randomised, Double blind, Parallel group, Placebo controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA) |
Ongoing |
Tozorakimab (MEDI3506) |
3 |
D9185C00001 |
King Abdulaziz Medical City NG (Jeddah), King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Riyadh) |
| Non-Interventional Study of the Change in Joint Health in Adult Patients with Haemophilia A after Switching to Prophylaxis with Turoctocog Alfa Pegol (N8-GP) |
Ongoing |
Turoctocog Alfa Pegol (N8-GP) |
4 |
NN7088-492 |
King Abdulaziz University Hospital (Jeddah),King Fahad Hospital (Jeddah) |
| Assessment of Quality of Life in Patients with Relapsing Multiple Sclerosis treated with Cladribine tablets in the Kingdom of Saudi Arabia |
Ongoing |
Cladribine |
4 |
MS700568-2 |
King Fahad Medical City (Riyadh),King Saud Medical City (Riyadh),King Abdulaziz Medical City NG (Riyadh),King Abdulaziz Medical City NG (Jeddah),King Faisal Specialist Hospital and Research Center (Jeddah),Dallah Hospital (Riyadh) |
| A Long-Term Extension Study of Nusinersen (BIIB058) Administered at Higher Doses in Participants With Spinal Muscular Atrophy Who Previously Participated in an Investigational Study With Nusinersen |
Ongoing |
Nusinersen (Spinraza) |
3 |
232SM302 |
King Faisal Specialist Hospital and Research Center (Riyadh),King Fahad Specialist Hospital (Dammam),King Abdulaziz Medical City NG (Jeddah) |
